Comprehensive molecular profiling of lung adenocarcinoma
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses. High rates of somatic mutation were seen (mean 8.9 mutations per megabase). Eighteen genes were statistically significantly mutated, including RIT1 activating mutations and newly described loss-of-function MGA mutations which are mutually exclusive with focal MYC amplification. EGFR mutations were more frequent in female patients, whereas mutations in RBM10 were more common in males. Aberrations in NF1, MET, ERBB2 and RIT1 occurred in 13% of cases and were enriched in samples otherwise lacking an activated oncogene, suggesting a driver role for these events in certain tumours. DNA and mRNA sequence from the same tumour highlighted splicing alterations driven by somatic genomic changes, including exon 14 skipping in MET mRNA in 4% of cases. MAPK and PI(3)K pathway activity, when measured at the protein level, was explained by known mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway activation. These data establish a foundation for classification and further investigations of lung adenocarcinoma molecular pathogenesis. An integrated transcriptome, genome, methylome and proteome analysis of over 200 lung adenocarcinomas reveals high rates of somatic mutations, 18 statistically significantly mutated genes including RIT1 and MGA, splicing changes, and alterations in MAPK and PI(3)K pathway activity. This report from The Cancer Genome Atlas Research Network presents molecular profiling of 230 resected untreated lung adenocarcinomas. Integrated analyses of transcriptome, genome, methylome and proteome collectively identify high rates of somatic mutation, significantly mutated genes including RIT1 and MGA, splicing alterations driven by somatic genomic changes, and point to as yet unidentified lesions that alter MAPK and PI(3)K pathway activity. These data establish a foundation for classification and further investigations of the leading cause of cancer death worldwide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Landmark large scale sequencing studies have established a census of major KRAS co-mutations in both early-stage and advanced LUAD15, 34, 59, 62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in PIK3CA and CTNNB1 are more frequent in advanced stage tumors compared with early stage LUADs, pointing towards functional roles in malignant progression and metastasis, whereas alterations in TP53 (62.5%), RB1 (9.5 −12.5%) and NKX2–1 (12.5%) appear to occur with comparable frequencies in early- and advanced-stage tumors15, 34, 72, 73.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“earlier studies that identified a central role for WNT signaling in LUAD metastasis”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,792
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446 · cited 1×
“Analysis of mutations in PIK3CA and STK11, STK11 protein levels, and AMPK and AKT phosphorylation(33) led to the identification of three major mTOR patterns in lung adenocarcinoma: (1) tumours with minimal or basal mTOR pathway activation, (2) tumours showing higher mTOR activity accompanied by either STK11-inactivati…”
BackgroundComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citationBhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Cited by
Items 201–300 of 1,045
Increased global transcription activity as a mechanism of replication stress in cancer
Kotsantis, P., Silva, L. M., Irmscher, S., Jones, R. M., Folkes, L., Gromak, N., & Petermann, E. (2016) · Nature Communications · doi:10.1038/ncomms13087 · Cited by 336
Mularoni, L., Sabarinathan, R., Deu-Pons, J., Gonzalez-Perez, A., & López-Bigas, N. (2016) · Genome Biology · doi:10.1186/s13059-016-0994-0 · Cited by 336
“…a tumor suppressor in the control of the activity of AMP-activated protein kinase (AMPK) family members, thereby playing a role in various processes such as cell metabolism, cell polarity, apoptosis, and DNA damage response, often bearing inactivating mutations in in lung adenocarcinomas [29, 30].”
BackgroundZEB1 drives epithelial-to-mesenchymal transition in lung cancer
Larsen, J. E., Nathan, V., Osborne, J. K., Farrow, R. K., Deb, D., Sullivan, J. P., Dospoy, P. D., Augustyn, A., Hight, S. K., Sato, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci76725 · Cited by 334
Onco-Multi-OMICS Approach: A New Frontier in Cancer Research
Chakraborty, S., Hosen, M. I., Ahmed, M., & Shekhar, H. U. (2018) · BioMed Research International · doi:10.1155/2018/9836256 · Cited by 335
Jänne, P. A., van den Heuvel, M. M., Barlesi, F., Cobo, M., Mazieres, J., Crinò, L., Orlov, S., Blackhall, F., Wolf, J., Garrido, P., et al. (2017) · JAMA · doi:10.1001/jama.2017.3438 · Cited by 335
Kris, M. G., Camidge, D. R., Giaccone, G., Hida, T., Li, B. T., O'Connell, J., Taylor, I., Zhang, H., Arcila, M. E., Goldberg, Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv186 · Cited by 334
Self-citationComprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients
Yuan, Y., Liu, L., Chen, H., Wang, Y., Xu, Y., Mao, H., Li, J., Mills, G. B., Shu, Y., Li, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.001 · Cited by 331
Recent advances in non-small cell lung cancer targeted therapy; an update review
Araghi, M., Mannani, R., Heidarnejad maleki, A., Hamidi, A., Rostami, S., Safa, S. H., Faramarzi, F., Khorasani, S., Alimohammadi, M., Tahmasebi, S., et al. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02990-y · Cited by 328
“Both of these drugs have been implicated in clinical trials and showed promising results, which caused to T-DXd drug to get FDA grant for HER2-mutant NSCLC and gastric cancer [182, 183].”
BackgroundThe impact of site-specific digital histology signatures on deep learning model accuracy and bias
Howard, F. M., Dolezal, J., Kochanny, S., Schulte, J., Chen, H., Heij, L., Huo, D., Nanda, R., Olopade, O. I., Kather, J. N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24698-1 · Cited by 330
Offin, M., Rizvi, H., Tenet, M., Ni, A., Sanchez-Vega, F., Li, B. T., Drilon, A., Kris, M. G., Rudin, C. M., Schultz, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1102 · Cited by 329
MET-dependent solid tumours — molecular diagnosis and targeted therapy
Guo, R., Luo, J., Chang, J., Rekhtman, N., Arcila, M., & Drilon, A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0377-z · Cited by 323
van der Pol, Y., & Mouliere, F. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.003 · Cited by 324
CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells
Kim, J., Hu, Z., Cai, L., Li, K., Choi, E., Faubert, B., Bezwada, D., Rodriguez-Canales, J., Villalobos, P., Lin, Y.-F., et al. (2017) · Nature · doi:10.1038/nature22359 · Cited by 325
Self-citationLower Airway Dysbiosis Affects Lung Cancer Progression
Tsay, J.-C. J., Wu, B. G., Sulaiman, I., Gershner, K., Schluger, R., Li, Y., Yie, T.-A., Meyn, P., Olsen, E., Perez, L., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0263 · Cited by 322
Ou, S.-H. I., Jänne, P. A., Leal, T. A., Rybkin, I. I., Sabari, J. K., Barve, M. A., Bazhenova, L., Johnson, M. L., Velastegui, K. L., Cilliers, C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02752 · Cited by 322
The evolution of lung cancer and impact of subclonal selection in TRACERx
Frankell, A. M., Dietzen, M., Al Bakir, M., Lim, E. L., Karasaki, T., Ward, S., Veeriah, S., Colliver, E., Huebner, A., Bunkum, A., et al. (2023) · Nature · doi:10.1038/s41586-023-05783-5 · Cited by 313
Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer
Shi, R., Radulovich, N., Ng, C., Liu, N., Notsuda, H., Cabanero, M., Martins-Filho, S. N., Raghavan, V., Li, Q., Mer, A. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1376 · Cited by 316
A radiogenomic dataset of non-small cell lung cancer
Bakr, S., Gevaert, O., Echegaray, S., Ayers, K., Zhou, M., Shafiq, M., Zheng, H., Benson, J. A., Zhang, W., Leung, A. N. C., et al. (2018) · Scientific Data · doi:10.1038/sdata.2018.202 · Cited by 311
Kong, N., Tao, W., Ling, X., Wang, J., Xiao, Y., Shi, S., Ji, X., Shajii, A., Gan, S. T., Kim, N. Y., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw1565 · Cited by 314
Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities
Kerr, E. M., Gaude, E., Turrell, F. K., Frezza, C., & Martins, C. P. (2016) · Nature · doi:10.1038/nature16967 · Cited by 313
Hurst, C. D., Alder, O., Platt, F. M., Droop, A., Stead, L. F., Burns, J. E., Burghel, G. J., Jain, S., Klimczak, L. J., Lindsay, H., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.08.005 · Cited by 311
TCGA Workflow: Analyze cancer genomics and epigenomics data using Bioconductor packages
Silva, T. C., Colaprico, A., Olsen, C., D'Angelo, F., Bontempi, G., Ceccarelli, M., & Noushmehr, H. (2016) · F1000Research · doi:10.12688/f1000research.8923.1 · Cited by 306
The NF1 somatic mutational landscape in sporadic human cancers
Philpott, C., Tovell, H., Frayling, I. M., Cooper, D. N., & Upadhyaya, M. (2017) · Human Genomics · doi:10.1186/s40246-017-0109-3 · Cited by 303
Padanad, M. S., Konstantinidou, G., Venkateswaran, N., Melegari, M., Rindhe, S., Mitsche, M., Yang, C., Batten, K., Huffman, K. E., Liu, J., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.009 · Cited by 301
“Activating mutations of the proto-oncogene KRAS 1614 Cell Reports 16, 1614–1628, August 9, 2016 ª 2016 The Author This is an open access article under the CC BY-NC-ND license (http:// (mutant KRAS) occur in 30% of the cases of non-small cell lung cancer (NSCLC) (Cancer Genome Atlas Research Network, 2014; Pylayeva-Gup…”
Zhang, Y., Du, W., Chen, Z., & Xiang, C. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.08.028 · Cited by 299
Deep learning-based prediction of the T cell receptor–antigen binding specificity
Lu, T., Zhang, Z., Zhu, J., Wang, Y., Jiang, P., Xiao, X., Bernatchez, C., Heymach, J. V., Gibbons, D. L., Wang, J., et al. (2021) · Nature Machine Intelligence · doi:10.1038/s42256-021-00383-2 · Cited by 295
Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them
Ramos, A., Sadeghi, S., & Tabatabaeian, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179451 · Cited by 289
“KEAP1 deletion confers chemoresistance in preclinical models of LUAD and LSCC. NSCLC patients with KEAP1/NFE2L2/CUL3 mutations have significantly shorter time to treatment failure (TTF) and overall survival (OS) when treated with first-line chemotherapy [39].”
BackgroundShih, D. J. H., Nayyar, N., Bihun, I., Dagogo-Jack, I., Gill, C. M., Aquilanti, E., Bertalan, M., Kaplan, A., D’Andrea, M. R., Chukwueke, U., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0592-7 · Cited by 289
Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma
Li, Y. Y., Hanna, G. J., Laga, A. C., Haddad, R. I., Lorch, J. H., & Hammerman, P. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1773 · Cited by 285
Marked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
Li, B. T., Michelini, F., Misale, S., Cocco, E., Baldino, L., Cai, Y., Shifman, S., Tu, H.-Y., Myers, M. L., Xu, C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0215 · Cited by 288
Scientific Advances in Lung Cancer 2015
Tsao, A. S., Scagliotti, G. V., Bunn, P. A., Carbone, D. P., Warren, G. W., Bai, C., de Koning, H. J., Yousaf-Khan, A. U., McWilliams, A., Tsao, M. S., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.03.012 · Cited by 284
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma
TRACERx Consortium, AbdulJabbar, K., Raza, S. E. A., Rosenthal, R., Jamal-Hanjani, M., Veeriah, S., Akarca, A., Lund, T., Moore, D. A., Salgado, R., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0900-x · Cited by 286
HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers
Li, B. T., Ross, D. S., Aisner, D. L., Chaft, J. E., Hsu, M., Kako, S. L., Kris, M. G., Varella-Garcia, M., & Arcila, M. E. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.025 · Cited by 286
Lung cancer epigenetics: From knowledge to applications
Duruisseaux, M., & Esteller, M. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.09.005 · Cited by 283
Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
Hughes, P. E., Caenepeel, S., & Wu, L. C. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.04.010 · Cited by 282
Lee, G., Lee, H. Y., Park, H., Schiebler, M. L., van Beek, E. J. R., Ohno, Y., Seo, J. B., & Leung, A. (2017) · European Journal of Radiology · doi:10.1016/j.ejrad.2016.09.005 · Cited by 282
A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data
Mo, Q., Shen, R., Guo, C., Vannucci, M., Chan, K. S., & Hilsenbeck, S. G. (2018) · Biostatistics · doi:10.1093/biostatistics/kxx017 · Cited by 280
Golding, B., Luu, A., Jones, R., & Viloria-Petit, A. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0810-4 · Cited by 273
Freed-Pastor, W. A., Lambert, L. J., Ely, Z. A., Pattada, N. B., Bhutkar, A., Eng, G., Mercer, K. L., Garcia, A. P., Lin, L., Rideout, W. M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.007 · Cited by 273
Kim, K.-T., Lee, H. W., Lee, H.-O., Kim, S. C., Seo, Y. J., Chung, W., Eum, H. H., Nam, D.-H., Kim, J., Joo, K. M., et al. (2015) · Genome Biology · doi:10.1186/s13059-015-0692-3 · Cited by 268
Clinical Implications of Genomic Discoveries in Lung Cancer
Swanton, C., & Govindan, R. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1504688 · Cited by 269
The genomic landscape of core-binding factor acute myeloid leukemias
Faber, Z. J., Chen, X., Gedman, A. L., Boggs, K., Cheng, J., Ma, J., Radtke, I., Chao, J.-R., Walsh, M. P., Song, G., et al. (2016) · Nature Genetics · doi:10.1038/ng.3709 · Cited by 269
Lissanu Deribe, Y., Sun, Y., Terranova, C., Khan, F., Martinez-Ledesma, J., Gay, J., Gao, G., Mullinax, R. A., Khor, T., Feng, N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0019-5 · Cited by 268
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
Majeed, U., Manochakian, R., Zhao, Y., & Lou, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01121-2 · Cited by 266
A Convergence-Based Framework for Cancer Drug Resistance
Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258
Molecular Pathways: Targeting ATR in Cancer Therapy
Karnitz, L. M., & Zou, L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0479 · Cited by 265
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer
Hrustanovic, G., Olivas, V., Pazarentzos, E., Tulpule, A., Asthana, S., Blakely, C. M., Okimoto, R. A., Lin, L., Neel, D. S., Sabnis, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3930 · Cited by 267
The kinome 'at large' in cancer
Fleuren, E. D. G., Zhang, L., Wu, J., & Daly, R. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.18 · Cited by 264
Dai, J., Lv, J., Zhu, M., Wang, Y., Qin, N., Ma, H., He, Y.-Q., Zhang, R., Tan, W., Fan, J., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30144-4 · Cited by 265
Deciphering the cells of origin of squamous cell carcinomas
Sánchez-Danés, A., & Blanpain, C. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0024-5 · Cited by 261
Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.
Kohno, T., Nakaoku, T., Tsuta, K., Tsuchihara, K., Matsumoto, S., Yoh, K., & Goto, K. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2014.11.11 · Cited by 263
Recent Advances in Targeting ROS1 in Lung Cancer
Lin, J. J., & Shaw, A. T. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.08.002 · Cited by 261
State-of-the-Art Strategies for Targeting RET-Dependent Cancers
Subbiah, V., Yang, D., Velcheti, V., Drilon, A., & Meric-Bernstam, F. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02551 · Cited by 258
Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer
Bar-Peled, L., Kemper, E. K., Suciu, R. M., Vinogradova, E. V., Backus, K. M., Horning, B. D., Paul, T. A., Ichu, T.-A., Svensson, R. U., Olucha, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.051 · Cited by 262
Vinayagam, A., Gibson, T. E., Lee, H.-J., Yilmazel, B., Roesel, C., Hu, Y., Kwon, Y., Sharma, A., Liu, Y.-Y., Perrimon, N., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603992113 · Cited by 257
Sacher, A. G., Dahlberg, S. E., Heng, J., Mach, S., Jänne, P. A., & Oxnard, G. R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4482 · Cited by 254
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
Grant, M. J., Herbst, R. S., & Goldberg, S. B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00520-1 · Cited by 255
EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors
Fillmore, C. M., Xu, C., Desai, P. T., Berry, J. M., Rowbotham, S. P., Lin, Y.-J., Zhang, H., Marquez, V. E., Hammerman, P. S., Wong, K.-K., et al. (2015) · Nature · doi:10.1038/nature14122 · Cited by 255
Identification of cancer driver genes based on nucleotide context
Dietlein, F., Weghorn, D., Taylor-Weiner, A., Richters, A., Reardon, B., Liu, D., Lander, E. S., Van Allen, E. M., & Sunyaev, S. R. (2020) · Nature Genetics · doi:10.1038/s41588-019-0572-y · Cited by 255
Wang, S., Jia, M., He, Z., & Liu, X.-S. (2018) · Oncogene · doi:10.1038/s41388-018-0245-9 · Cited by 254
AMPK signaling and its targeting in cancer progression and treatment
Hsu, C.-C., Peng, D., Cai, Z., & Lin, H.-K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.006 · Cited by 246
Diederichs, S., Bartsch, L., Berkmann, J. C., Fröse, K., Heitmann, J., Hoppe, C., Iggena, D., Jazmati, D., Karschnia, P., Linsenmeier, M., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506055 · Cited by 253
Systematic investigation of cytokine signaling activity at the tissue and single-cell levels
Jiang, P., Zhang, Y., Ru, B., Yang, Y., Vu, T., Paul, R., Mirza, A., Altan-Bonnet, G., Liu, L., Ruppin, E., et al. (2021) · Nature Methods · doi:10.1038/s41592-021-01274-5 · Cited by 244
Translational advances in pancreatic ductal adenocarcinoma therapy
Hosein, A. N., Dougan, S. K., Aguirre, A. J., & Maitra, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00349-2 · Cited by 250
Single-cell RNA sequencing reveals distinct tumor microenvironmental patterns in lung adenocarcinoma
Bischoff, P., Trinks, A., Obermayer, B., Pett, J. P., Wiederspahn, J., Uhlitz, F., Liang, X., Lehmann, A., Jurmeister, P., Elsner, A., et al. (2021) · Oncogene · doi:10.1038/s41388-021-02054-3 · Cited by 248
Yuan, X., Wu, H., Han, N., Xu, H., Chu, Q., Yu, S., Chen, Y., & Wu, K. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0087-z · Cited by 248
Wohlhieter, C. A., Richards, A. L., Uddin, F., Hulton, C. H., Quintanal-Villalonga, À., Martin, A., de Stanchina, E., Bhanot, U., Asher, M., Shah, N. S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108444 · Cited by 246
“Approximately 17% of patients with LUAD have loss-of-function mutations in KEAP1 (Collisson et al., 2014).”
Lee, S.-H., Lee, J.-K., Ahn, M.-J., Kim, D.-W., Sun, J.-M., Keam, B., Kim, T. M., Heo, D. S., Ahn, J. S., Choi, Y.-L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw559 · Cited by 244
Decker, W. K., da Silva, R. F., Sanabria, M. H., Angelo, L. S., Guimarães, F., Burt, B. M., Kheradmand, F., & Paust, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00829 · Cited by 246
Targeting Oncogenic BRAF: Past, Present, and Future
Zaman, A., Wu, W., & Bivona, T. G. (2019) · Cancers · doi:10.3390/cancers11081197 · Cited by 245
Genomic and immune profiling of pre-invasive lung adenocarcinoma
Chen, H., Carrot-Zhang, J., Zhao, Y., Hu, H., Freeman, S. S., Yu, S., Ha, G., Taylor, A. M., Berger, A. C., Westlake, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13460-3 · Cited by 243
Herbst, R. S., Gandara, D. R., Hirsch, F. R., Redman, M. W., LeBlanc, M., Mack, P. C., Schwartz, L. H., Vokes, E., Ramalingam, S. S., Bradley, J. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3473 · Cited by 244
Ferone, G., Song, J.-Y., Sutherland, K. D., Bhaskaran, R., Monkhorst, K., Lambooij, J.-P., Proost, N., Gargiulo, G., & Berns, A. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.001 · Cited by 244
Singhal, S., Stadanlick, J., Annunziata, M. J., Rao, A. S., Bhojnagarwala, P. S., O’Brien, S., Moon, E. K., Cantu, E., Danet-Desnoyers, G., Ra, H.-J., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat1500 · Cited by 244
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer
Alam, H., Tang, M., Maitituoheti, M., Dhar, S. S., Kumar, M., Han, C. Y., Ambati, C. R., Amin, S. B., Gu, B., Chen, T.-Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.005 · Cited by 243
“Our results uncover a inactivating mutations induce aberrant metabolic reprogramm ings support a glycolysis-inhibitory approach as a therapeutic characterized by gain-of-function mutations and amplification of oncogenic kinase genes (e.g., KRAS and EGFR) as well as lossof-function alterations in tumor-suppressor genes…”
BackgroundInfluentialGene aberrations for precision medicine against lung adenocarcinoma
Saito, M., Shiraishi, K., Kunitoh, H., Takenoshita, S., Yokota, J., & Kohno, T. (2016) · Cancer Science · doi:10.1111/cas.12941 · Cited by 240
Machine learning of serum metabolic patterns encodes early-stage lung adenocarcinoma
Huang, L., Wang, L., Hu, X., Chen, S., Tao, Y., Su, H., Yang, J., Xu, W., Vedarethinam, V., Wu, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17347-6 · Cited by 240
Genomic and evolutionary classification of lung cancer in never smokers
Zhang, T., Joubert, P., Ansari-Pour, N., Zhao, W., Hoang, P. H., Lokanga, R., Moye, A. L., Rosenbaum, J., Gonzalez-Perez, A., Martínez-Jiménez, F., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00920-0 · Cited by 238
Targeting Rac and Cdc42 GTPases in Cancer
Maldonado, M. D. M., & Dharmawardhane, S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0619 · Cited by 237
The Role of EREG/EGFR Pathway in Tumor Progression
Cheng, W.-L., Feng, P.-H., Lee, K.-Y., Chen, K.-Y., Sun, W.-L., Van Hiep, N., Luo, C.-S., & Wu, S.-M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312828 · Cited by 239
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment
Kerk, S. A., Papagiannakopoulos, T., Shah, Y. M., & Lyssiotis, C. A. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00375-9 · Cited by 237
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
Xiong, J., Cui, B.-W., Wang, N., Dai, Y.-T., Zhang, H., Wang, C.-F., Zhong, H.-J., Cheng, S., Ou-Yang, B.-S., Hu, Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.02.005 · Cited by 233
Wang, C., Yu, Q., Song, T., Wang, Z., Song, L., Yang, Y., Shao, J., Li, J., Ni, Y., Chao, N., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01130-8 · Cited by 231
Resisting Resistance: Targeted Therapies in Lung Cancer
Lin, J. J., & Shaw, A. T. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.05.010 · Cited by 232
The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2
Hartwig, T., Montinaro, A., von Karstedt, S., Sevko, A., Surinova, S., Chakravarthy, A., Taraborrelli, L., Draber, P., Lafont, E., Arce Vargas, F., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.01.021 · Cited by 234
“…expression data, we subjected RNA sequencing (RNA-seq) data from a cohort of 489 lung adenocarcinoma (LUAD) patients (Cancer Genome Atlas Research Network, 2014), obtained from the Cancer Genome Atlas (TCGA) (https://cancergenome.nih.gov/), to 738 Molecular Cell 65, 730–742, February 16,…”
MethodRodak, O., Peris-Díaz, M. D., Olbromski, M., Podhorska-Okołów, M., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13184705 · Cited by 233
“6% of NSCLC patients, while other sources estimated that it accounts for about 8% of lung adenocarcinomas [48,154].”
BackgroundTracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma
Lee, J. J.-K., Park, S., Park, H., Kim, S., Lee, J., Lee, J., Youk, J., Yi, K., An, Y., Park, I. K., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.013 · Cited by 233
Biology and evolution of poorly differentiated neuroendocrine tumors
Rickman, D. S., Beltran, H., Demichelis, F., & Rubin, M. A. (2017) · Nature Medicine · doi:10.1038/nm.4341 · Cited by 231
Sayin, V. I., LeBoeuf, S. E., Singh, S. X., Davidson, S. M., Biancur, D., Guzelhan, B. S., Alvarez, S. W., Wu, W. L., Karakousi, T. R., Zavitsanou, A. M., et al. (2017) · eLife · doi:10.7554/elife.28083 · Cited by 231
Gwinn, D. M., Lee, A. G., Briones-Martin-del-Campo, M., Conn, C. S., Simpson, D. R., Scott, A. I., Le, A., Cowan, T. M., Ruggero, D., & Sweet-Cordero, E. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.003 · Cited by 230
Labbé, C., Cabanero, M., Korpanty, G. J., Tomasini, P., Doherty, M. K., Mascaux, C., Jao, K., Pitcher, B., Wang, R., Pintilie, M., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.06.014 · Cited by 230
Cancer proteogenomics: current impact and future prospects
Mani, D. R., Krug, K., Zhang, B., Satpathy, S., Clauser, K. R., Ding, L., Ellis, M., Gillette, M. A., & Carr, S. A. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00446-5 · Cited by 229
Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?
Pietanza, M. C., Byers, L. A., Minna, J. D., & Rudin, C. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2958 · Cited by 228
Clinical cancer genomic profiling
Chakravarty, D., & Solit, D. B. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00338-8 · Cited by 226
Mutational signatures are jointly shaped by DNA damage and repair
Volkova, N. V., Meier, B., González-Huici, V., Bertolini, S., Gonzalez, S., Vöhringer, H., Abascal, F., Martincorena, I., Campbell, P. J., Gartner, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15912-7 · Cited by 228
Inferring gene expression from cell-free DNA fragmentation profiles
Esfahani, M. S., Hamilton, E. G., Mehrmohamadi, M., Nabet, B. Y., Alig, S. K., King, D. A., Steen, C. B., Macaulay, C. W., Schultz, A., Nesselbush, M. C., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01222-4 · Cited by 221
Mechanisms of Acquired Resistance to AZD9291
Kim, T. M., Song, A., Kim, D.-W., Kim, S., Ahn, Y.-O., Keam, B., Jeon, Y. K., Lee, S.-H., Chung, D. H., & Heo, D. S. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000688 · Cited by 222
Li, Z., Ivanov, A. A., Su, R., Gonzalez-Pecchi, V., Qi, Q., Liu, S., Webber, P., McMillan, E., Rusnak, L., Pham, C., et al. (2017) · Nature Communications · doi:10.1038/ncomms14356 · Cited by 219
Targeting MET Dysregulation in Cancer
Recondo, G., Che, J., Jänne, P. A., & Awad, M. M. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1446 · Cited by 221
“De novo MET amplification occurs in ~1% of NSCLC and has been associated with poor survival in patients with surgically resected early-stage disease (50,57,58).”
Background
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2014-07-09
- Volume
- 511
- Issue
- 7511
- Pages
- 543-550
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4231481
- OpenAlex
- W2180481128
- Cited by
- 5,732
- References
- 42
- Citations by year
- 2026: 314 · 2025: 415 · 2024: 428 · 2023: 523 · 2022: 547 · 2021: 614 · 2020: 613 · 2019: 495 · 2018: 478 · 2017: 516 · 2016: 427 · 2015: 312 · 2014: 47
- FWCI
- 347.50
- Type
- journal article
- Language
- en
- Update notices
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc-sa)
- SERVAL (Université de Lausanne) (acceptedVersion, cc-by-nc-sa)
- eScholarship (California Digital Library) (submittedVersion)
- IRIS (submittedVersion, cc-by-nc-sa)
- eSpace (Curtin University) (submittedVersion)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (UL1TR000005)
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273, R01HG006272)
- National Cancer Institute (U24CA126554, U24CA143882, U24CA143843, U24CA143840, U24CA126546, CA143883, U24CA143858, K08CA137153, U24CA126543, U24CA144025, U24CA126563, U24CA143866, U24CA143883, CA143840, U24 CA137153, U24CA143845, U24CA126544, U24CA180951, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, P30CA177558, P30CA008748, P30CA016672, P30CA006973)
- National Institute of General Medical Sciences (T32GM007753)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung adenocarcinoma, somatic mutations, RIT1, MGA, MYC amplification, EGFR mutation, RBM10, neurofibromatosis type 1, MET, ERBB2, MET exon 14 skipping, splicing alterations, MAPK signaling, PI3K signaling, DNA methylation, microRNA, transcriptome, proteome, molecular classification, carcinogenesis
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Female, Humans, Lung Neoplasms, Male, Mutation, Oncogenes, Sex Factors, Gene Expression Regulation, Neoplastic, Gene Dosage, Cell Cycle Proteins, Genomics, Molecular Typing, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.